Skip to main content

NOX enzymes as mediators of inflammation-triggered neurodegeneration: modulating NOX enzymes as novel therapies

Objective

NEURINOX aims at elucidating the role of NADPH oxidases (NOX) in neuroinflammation and its progression to neurodegenerative diseases (ND), as well as evaluating the potential of novel ND therapeutics approaches targeting NOX activity. NOX generate reactive oxygen species (ROS) and have emerged as regulators of neuroinflammation. Their role is complex: ROS generated by NOX lead to tissue damage in microglia-mediated neuroinflammation, as seen in amyotrophic lateral sclerosis (ALS), while absence of ROS generation enhances the severity of autoimmune-mediated neuroinflammation, as seen for e.g. in multiple sclerosis (MS).
The objective of the 5 years NEURINOX project is to understand how NOX controls neuroinflammation, identify novel molecular pathways and oxidative biomarkers involved in NOX-dependent neuroinflammation, and develop specific therapies based on NOX modulation. The scientific approach will be to: (i) identify NOX-dependent molecular mechanisms using dedicated ND animal models (ii) develop therapeutic small molecules either inhibiting or activating NOX and test their effects in animal models (iii) test the validity of identified molecular pathways in clinical studies in ALS and MS patients.
NEURINOX will contribute to better understand brain dysfunction, and more particularly the link between neuroinflammation and ND and to identify new therapeutic targets for ND. A successful demonstration of the benefits of NOX modulating drugs in ALS and MS animal models, and in ALS early clinical trials will validate a novel high potential therapeutics target for ALS and also many types of ND. NEURINOX has hence a strong potential for more efficient ND healthcare for patients and thus for reducing ND healthcare costs.
This multi-disciplinary consortium includes leading scientists in NOX research, ROS biology, drug development SMEs, experts in the neuroinflammatory aspects of ND, genomics and proteomics, and clinicians able to translate the basic science to the patient.

Field of science

  • /medical and health sciences/basic medicine/neurology/amyotrophic lateral sclerosis
  • /medical and health sciences/basic medicine/neurology/multiple sclerosis
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/proteomics
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins/enzymes

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-IP - Large-scale integrating project

Coordinator

UNIVERSITE DE GENEVE
Address
Rue Du General Dufour 24
1211 Geneve
Switzerland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 493 755,95
Administrative Contact
Karl-Heinz Krause (Prof.)

Participants (14)

UNIVERSITE JOSEPH FOURIER GRENOBLE 1

Participation ended

France
Address
Avenue Centrale, Domaine Universitaire 621
38041 Grenoble
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sophie Beaubron (Ms.)
UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 1 086 940
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Adriano Aguzzi (Prof.)
GENKYOTEX INNOVATION SAS
France
EU contribution
€ 1 129 402
Address
Domaine De Chosal
74160 Archamps
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Rebecca Margarito (Ms.)
REDOXIS AB
Sweden
EU contribution
€ 770 800
Address
Medicon Village Scheelevagen 2
223 81 Lund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Peter Olofsson (Dr.)
ARTTIC
France
EU contribution
€ 560 341
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Eric Papon (Dr.)
UNIVERSITA DEGLI STUDI DI TORINO
Italy
EU contribution
€ 866 670
Address
Via Giuseppe Verdi 8
10124 Torino
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Donatella Amadori (Ms.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 1 983 090
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jill Blomstrand (Ms.)
UNIVERSITE GRENOBLE ALPES
France
EU contribution
€ 941 556
Address
621, Avenue Centrale
38401 Grenoble
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sophie Beaubron (Ms.)
SYNAPCELL
France
EU contribution
€ 683 000
Address
Zone D' Activite Commerciale Isiparc Village Scien
38330 Saint Ismier
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Yann Roche (Dr.)
IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Greece
EU contribution
€ 1 158 090,05
Address
Soranou Efesiou 4
115 27 Athina
Activity type
Research Organisations
Administrative Contact
Dimitris Raptis (Mr.)
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON
Greece
EU contribution
€ 401 450
Address
6 Christou Lada Str
10561 Athina
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Efstathia Kafentzi (Ms.)
THE UNIVERSITY OF SYDNEY

Participation ended

Australia
Address
Camperdown Campus Arundel St 71/79
2006 Sydney
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Kate Taylor (Ms.)
NEURIX SA
Switzerland
EU contribution
€ 350 000
Address
Avenue De La Roseraie 64
1205 Geneve
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Samuel Constant (Dr.)
VICTOR CHANG CARDIAC RESEARCH INSTITUTE LIMITED LBG
Australia
Address
Liverpool Street 405
2010 Darlinghurst
Activity type
Research Organisations
Administrative Contact
Kiran Narsey (Mr.)